Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi STA Pharma Forms Drug Delivery Collaboration with BioLingus

publication date: Feb 21, 2019

WuXi STA Pharma, the small molecule manufacturing subsidiary of China's largest CRO, WuXi AppTec (SHA: 603259; HK: 2359), will collaborate with Switzerland's BioLingus to provide sublingual delivery formulations. WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. BioLingus' proprietary technology forms injected small molecule, peptide and protein drugs to be administered sublingually (orally under the tongue). WuXi STA offers process development and manufacturing services to global pharmas. More details....


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital